# Focused Orticumab Research for Treating Inflammation in Coronary Arteries

Study · id `cardio:ct-nct06927739` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06927739](<https://clinicaltrials.gov/study/NCT06927739>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06927739

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.

## Technical summary

Registry record NCT06927739. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-11 (actual); primary completion 2027-02-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT06927739, source copy `cardio:ctgov-nct06927739-2026-01-27`, retrieved 2026-10-26)
- Started: 2025-08-11 (actual) (ClinicalTrials.gov record NCT06927739, source copy `cardio:ctgov-nct06927739-2026-01-27`, retrieved 2026-10-26)
- Primary completion: 2027-02-08 (anticipated) (ClinicalTrials.gov record NCT06927739, source copy `cardio:ctgov-nct06927739-2026-01-27`, retrieved 2026-10-26)
- Completion: 2027-06-01 (anticipated) (ClinicalTrials.gov record NCT06927739, source copy `cardio:ctgov-nct06927739-2026-01-27`, retrieved 2026-10-26)
- Countries: United States; Czechia; Hungary; Italy; Poland; Romania; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT06927739, source copy `cardio:ctgov-nct06927739-2026-01-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06927739-2026-01-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Focused Orticumab Research for Treating Inflammation in Coronary Arteries
- Acronym: FORTIFY
- Condition: Acute Coronary Syndromes
- Condition: Coronary Arterial Disease (CAD)
- Condition: Inflammation
- Condition: Heart Disease
- Condition: Myocardial Infarct
- Condition: Atherosclerotic Coronary Vascular Disease
- Intervention (Drug): Orticumab
- Intervention (Drug): Placebo
- Lead sponsor: Abcentra
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)

## Provenance

Content hash: a530bb064d834d4046c6d7f2ce1a41aef6070ef6cef748ec1e7c472f5401d45e
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
